Clinical Trial

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.
Trial Details
NCT Number NCT05553093
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Conditions Type 2 Diabetes Mellitus
Enrollment 150 participants
Start Date 2022-03-15
Primary Completion 2023-12-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2022-09-23